Bristol Myers Squibb, US1101221083

Bristol Myers Squibb stock: FDA accepts second molecular glue IND

Published on 11/19/2026 at 12:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bristol Myers Squibb stock enters a fresh research milestone through its Evotec partnership. A second candidate is expected to begin a Phase 1 trial in 2027.

Second candidate advances toward clinical testing

  • FDA acceptance moves a second molecular glue candidate from the Evotec-Bristol Myers Squibb partnership toward a planned Phase 1 trial.
  • The collaboration combines Evotec's discovery platforms with Bristol Myers Squibb's CELMoD compound library.
  • The first partnership candidate entered a Phase 1 study in advanced clear cell renal cell carcinoma in March 2026.
Bristol Myers Squibb, US1101221083, Illustration mit AI erstellt.

On Thursday, November 19, 2026, Evotec said in a press release published by PR Newswire that its strategic protein-degradation partnership with Bristol Myers Squibb had received a second Investigational New Drug acceptance from the U.S. Food and Drug Administration.

Partnership expands clinical pipeline

The accepted candidate is a cereblon E3 ligase modulator, or CELMoD, and is expected to enter a Phase 1 clinical trial in 2027. The first candidate produced under the partnership entered a Phase 1 trial for advanced clear cell renal cell carcinoma in March 2026.

The collaboration began in 2018 with Celgene, which is now part of Bristol Myers Squibb, and was expanded in 2022. Evotec contributes its multi-omics screening, PanOmics and PanHunter platforms, as well as AI-supported drug discovery capabilities. Bristol Myers Squibb contributes its CELMoD agent library.

Evotec Chief Scientific Officer Joanna Holbrook said the second candidate's progression to IND acceptance demonstrated the repeatability and productivity of the discovery platform. The release said the partnership is intended to advance molecular glue degraders for oncology and other therapeutic areas.

Stock quote remains a separate signal

Bristol Myers Squibb stock traded at 53.93 euros on Lang & Schwarz at 12:40 CET on Thursday, November 19, 2026.

The FDA step expands the partnership's research pipeline, while the clinical value of the second candidate will depend on later trial results. Investors will therefore focus on the start of the planned Phase 1 study and subsequent safety and efficacy updates.

Bristol Myers Squibb company facts

  • Company: Bristol-Myers Squibb Co.
  • ISIN: US1101221083
  • WKN: 850501
  • Quote: 53.93 euros on Lang & Schwarz, 12:40 CET, November 19, 2026

The S&P 500 provides the relevant US market context for the company.

More news and analyses on Bristol Myers Squibb stock

Disclaimer...
en | US1101221083 | BRISTOL MYERS SQUIBB | boerse | 70535602 | bgmi